Order Article Reprints

Fani M, Weingaertner V, Kolenc Peitl P, Mansi R, Gaonkar RH, Garnuszek P, Mikolajczak R, Novak D, Simoncic U, Hubalewska-Dydejczyk A, et al. Selection of the First ^99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates. Pharmaceuticals. 2021; 14(1):19. https://doi.org/10.3390/ph14010019

Fani, Melpomeni, Viktoria Weingaertner, Petra Kolenc Peitl, Rosalba Mansi, Raghuvir H. Gaonkar, Piotr Garnuszek, Renata Mikolajczak, Doroteja Novak, Urban Simoncic, Alicja Hubalewska-Dydejczyk, and et al. 2021. "Selection of the First ^99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates" Pharmaceuticals 14, no. 1: 19. https://doi.org/10.3390/ph14010019

Fani, M., Weingaertner, V., Kolenc Peitl, P., Mansi, R., Gaonkar, R. H., Garnuszek, P., Mikolajczak, R., Novak, D., Simoncic, U., Hubalewska-Dydejczyk, A., Rangger, C., Kaeopookum, P., & Decristoforo, C. (2021). Selection of the First ^99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates. Pharmaceuticals, 14(1), 19. https://doi.org/10.3390/ph14010019